Autofluorescence and diagnostic accuracy of lesions of oral mucosa: a pilot study by Jané Salas, Enric et al.
The purpose of this study was to determine the accuracy of autofluorescence techniques 
for diagnosing oral mucosa lesions, using as reference pattern for comparison the visual 
diagnosis made by a clinical specialist. A pilot study was conducted with 60 patients 
divided in a control group without mucosal pathology and a study group with known 
clinical history for mucosal pathology. Both groups were examined by an oral medicine 
specialist and by a general dentist who used VELscope® system, which applies tissue 
fluorescence visualization to identify oral mucosal abnormalities. Using the VELscope® 
system, the general dentist made overdiagnosis in two cases and underdiagnosis in one 
case. The sensitivity and specificity for the oral medicine specialist were 1 (95% CI: 0.884 
to 1). For the general dentist, the sensitivity did not improve significantly with the use 
of VELscope® system [0.53 (95% CI: 0.343 to 0.717) versus 0.49 (95% CI: 0.406 to 0.773)] 
and the specificity was 0.80 (95% CI: 0.614 to 0.923). A limitation of the study is the 
small sample size, which does not fully represent a population and extrapolation of the 
data should be done carefully. Based on the obtained results, no clinical benefits were 
obtained using this VELscope® system. 
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Introduction
The early detection of diseases in the oral mucosa 
and potentially malignant disorders (1) requires a careful 
tracking of potentially malignant lesions given the high 
frequency of malignant transformation and has critical 
importance regarding a patient’s best interest (2). Prognosis 
depends widely on the stage of the pathologies when 
detected and treated, and so early detection is the most 
effective method to reduce morbidity and mortality. 
In the last few decades, given the importance of early 
detection of premalignant dysplasia or oral cancer, some 
complementary diagnostic systems were introduced to 
improve and facilitate the identification of oral lesions 
and subjacent oral diseases, such as VELscope® (Visually 
Enhanced Lesion Scope) system (3). This hand-held device 
developed by LED Dental Inc., a wholly-owned US subsidiary 
of LED Medical Diagnostics Inc., White Rock, BC, Canada) in 
association with British Columbia Cancer Agency, uses the 
basic premise of tissue fluorescence visualization, which is 
identifying changes in oral mucosal tissues by observing the 
fluorescence of oral tissues in response to light excitation. 
This system detects the loss of fluorescence in visible and 
not visible high-risk lesions using a handpiece emitting 
light at 400-460 nm wavelength range. Under this light, 
the normal mucosa emits green color fluorescence while 
the abnormal area absorbs the fluorescent light and dark 
patches appear. Therefore, it detects the early biochemical 
changes in oral disease and, theoretically, allows the early 
detection of pathological lesions. The VELscope® system 
sends a blue light into the oral cavity, which excites the 
surface of the epithelium through the basement membrane 
and stroma, causing fluorescence. The clinician is then able 
to see immediately the different kinds of fluorescence 
response, which aids distinguishing the contrast between 
normal and abnormal tissue (4,5). 
The physiopathological concept that explains tissue 
autofluorescence response is based on changes in the cell 
structure (such as hyperkeratosis, hypercromatine, increase 
in pleomorphism, variations in nucleus size and even cell 
volume) and metabolism (concentration of flavin adenine 
and nicotinamide adenine dinucleotide in epithelial and in 
subepithelial stroma). In particular, these changes in the 
epithelium and in the stroma, may alter the distribution of 
the fluorophores in the tissues and consequently the way 
by which the fluorescence is emitted after been stimulated 
by the blue light (2,6). Hemoglobin strongly absorbs the 
autofluorescent light produced by collagen and elastin. 
More specifically, the increased presence of submucous 
blood associated with oral cancer and its angiogenesis 
process may enhance the absorption of collagen and 
elastin produced by the autofluorescent light, this is why 
the area may appear darker during the examination with 
VELscope® (7-10). 
The use of autofluorescence for detection of malignant 
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lesions was provided by photodynamic therapy, a technique 
used clinically to treat cancer. During this therapy, the light-
sensitive drug (photosensitizer) is introduced in the tumour 
either by systemic or local application using a precursor 
such as protoporphyrin IX. The photosensitizer produces free 
oxygen which, when excited by light application at specific 
wavelength, damages the cell organelles causing cell 
death. It is believed that certain sensitizers accumulating 
in malignant tissues can be useful for its diagnosis.
By the end of 1970, autofluorescence, also known as 
endogenous fluorescence of the tissues, was employed for 
detection of the exogenous fluorescence that could be 
useful for the detection of cancer (11). Moreover, it has 
been used for the early detection and diagnosis of pre-
cancer and cancer lesions in lungs, cervix, skin and more 
recently, the oral cavity. 
Tissue fluorescence visualization systems can be 
helpful to detect a wide variety of premalignant and 
malignant lesions in addition playing a crucial role in the 
delineation of the surgical margin, treatment and even 
follow-up (8,12). 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































of VELscope® for diagnosis of oral mucosa lesions may 
improve the diagnostic accuracy when compared with 
direct clinical examination. Another goal was to define the 
role of systematic and meticulous clinical examinations as 
useful tools in the diagnosis of oral lesions.
Material and Methods
A validation of the study was carried out and it was 
approved by the ethics committee of the Dental School, 
University of Barcelona and the University Hospital of 
Bellvitge. The protocol number of the ethics committee 
of the University Hospital of Bellvitge is PR049/10 dated 
08/07/2010.
Study Population and Sample
This study was carried out with two groups of 30 
patients with or without previous diagnosed pathology 
in the mucosa of the oral cavity. A convenience sampling 
scheme was used by reviewing the clinical history of all 
patients who attended the Dental Clinic of the University 
of Barcelona and had been previously treated at the Master 
degree Programs of Dental Surgery and/or Oncology 
and Immunocompromised Patients of the University of 
Barcelona, Spain. The patients were informed about the 
purpose of the study, agreed 
to participate voluntarily and 
signed an informed consent 
form. Patients with confirmed 
diagnosis of squamous cell 
carcinoma; with injuries or 
biopsy surgeries of suspicious 
areas; with clinical and/or 
previous histopathological 
diagnosis of oral carcinoma; 
with a diagnosis of lesion of 
unknown origin or confirmed 
or highly suspected malignancy, 
were not included.
The study group (thereafter 
SG) was formed by recruiting 
the first 30 patients with a 
diagnostic record in their 
clinical history of some oral 
pathology. All suspicious lesions 
were diagnosed by biopsy and 
histopathology. The control 
group (thereafter CG) was also 
formed by recruiting the first 30 
patients without any previous 
record of oral mucosal disease 
in their clinical history. Thus, 
information about the presence 
of oral mucosa pathology from 
patient’s clinical history was 
used as a reference diagnostic 
parameter. The study was 
performed between the 
beginning of June and the 
end of July, 2013.
Main Variables
a) Expert diagnosis (made 
by an oral medicine specialist); 






















































































































































































































































































































































































































































































































































































































































































































































































































































by a general dentist) and; c) VELscope® aided inexpert 
diagnosis. All three outcomes were originally recorded 
as positive (+): some oral mucosa pathology detected), 
negative (-): no oral mucosa pathology detected) and 
doubtful (+/-): no definitive decision was made. For the 
analysis and comparisons of diagnostic accuracy, original 
doubtful scores were reassigned as positive (+). 
Secondary Variables
Size and location of the detected lesions by both 
examiners and the VELscope® system.
Systematization of the Study
The same evaluation protocol was followed for all 
patients. Both examiners (expert and inexpert) were blinded 
to group assignment, did not have access to the patient´s 
clinical history and did not carry out patient anamnesis.
Expert Diagnosis
An experienced specialist examiner (J.L.L.) with 
more than 5 years of experience in the diagnosis of oral 
pathologies carried out a detailed and rigorous examination 
of the oral cavity, emphasizing the presence of lesions 
or changes in the surface of the tissues. The presence of 
lesions and their location were recorded with the aid of 
the diagram proposed by Roed-Petersen and Renstrup (13) 
and a clinical diagnosis was established. To compare and 
reproduce the obtained data as well produce a detailed 
mapping of oral cavity, pictures of the suspicious areas 
and other locations were taken using a Sony model α 350 
(Tokyo, Japan): 1. Retromolar right area, 2. Retromolar left 
area, 3. Right oral mucosa, 4. Left oral mucosa, 5. Dorsal 
tongue, 6. Right border of the tongue, 7. Left border of the 
tongue, 8. Floor of the mouth, 9. Upper vestibular gingival, 
10. Lower vestibular gingival. .
Inexpert Diagnosis 
An examiner (F.D.L) with more than 2 years of experience 
since graduation and blinded to the expert diagnosis, 
proceeded with an exhaustive exploration of the oral cavity 
looking for the presence of any alterations or lesions. The 
presence of lesions and their location were recorded with 
the aid of the diagram proposed by Roed-Petersen and 
Renstrup (13) and a clinical diagnosis was established. 
Pictures of the suspicious areas as well as the other locations 
were taken, as previously mentioned.
VELScope® Aided Inexpert Diagnosis 
Immediately after the previous examination, the same 
non-specialist examiner, who had received training on the 
use of the device, explored the oral cavity using VELScope®, 
in a environment with no kind of illumination (Fig. 1). The 
presence of lesions and their location were recorded with 
the aid of the diagram proposed by Roed-Petersen and 
Figure 1. A: Clinical image of the lesion. B: Visualization with VELscope®.












Table 2. Summary table of diagnostic assignment in three categories (+ with lesion, +/−doubt and − without lesion) obtained from three independent 
evaluations on 60 examined individuals
Reference test
Expert diagnosis Inexpert diagnosis Velscope-aided inexpert diagnosis
+ +/− − + +/− − + +/− −
Study Group
(with lesion)
count 26 4 0 9 7 14 10 8 12
n=30 (0.87) (0.13) (0.0) (0.30) (0.23) (0.47) (0.33) (0.27) (0.40)
Control Group
(without lesion)
count 0 0 30 5 0 25 6 0 24
n=30 (0.0) (0.0) (1.0) (0.17) (0.0) (0.83) (0.20) (0.0) (0.80)
Total
count 26 4 30 14 7 39 16 8 36
 n=60 (0.43) (0.07) (0.50) (0.23) (0.12) (0.65) (0.27 (0.13) (0.60)





























Renstrup (13) and a clinical diagnosis was established. 
Pictures of the suspicious areas as well as the other locations 
were taken, as previously mentioned. 
Statistical Analysis
Confidence intervals for proportions were estimated 
using Clopper-Pearson exact procedure (14). Agreement 
between diagnostic procedures was assessed using Cohen’s 
kappa statistic. McNemar test for paired proportions with 
Montecarlo approach were also used. Statistical analyses 
were carried out using PASW v. 18.0 software. The STARD 
checklist was applied  for reporting of studies of diagnostic 
accuracy (version January 2003)(15). 
Results
Summary of the recorded data is shown in Tables 2 and 
3. Regarding diagnostic accuracy, the estimated values for 
sensitivity and specificity were both 1 (95% CI: 0.884 to 
1) for expert diagnosis. Performance of inexpert diagnosis 
decreases, showing a 0.53 sensitivity (95% CI: 0.343 to 
0.717) and 0.83 specificity (95% CI: 0.653 to 0.944). With 
the use of VELscope® the diagnostic performance of the 
inexpert examiner is not improved, obtaining a sensitivity 
of 0.40 (95% CI: 0.406 to 0.773) and a specificity of 0.80 
(95% CI: 0.614 to 0.923). Expert and inexpert diagnosis show 
a relative low agreement of κ=0.37 (95% CI: 0.14 to 0.59), 
whereas unaided and VELscope® aided inexpert diagnosis 
shows a good agreement of κ=0.75 (95% CI: 0.58 to 0.92). 
Comparing the proportion of positive diagnostics 
between unaided and VELscope® aided inexpert diagnosis 
we found that there is no significant difference in the 
paired proportions (McNemar chi-square=1.3, montecarlo 
p-value=0.45). 
Discussion
The clinical examination of the oral tissues delivers 
diagnosis, which needs to be confirmed by the 
histopathological examination of biopsied tissue samples. 
For this reason, a wide variety of studies have tried to assess 
the effectiveness of the VELscope® system as an adjuvant 
of visual examination to improve the detection of lesions. 
Among them is the series of 112 patients examined by 
Farah et al. (16), the clinical examination using VELScope® 
showed a sensitivity of 30% and a specificity of 63%. Its 
accuracy at identifying dysplasia was 55%. Our study shows 
that, based on the  sensitivity and specificity, VELscope® 
aided diagnosis does not appear to be more accurate 
than unaided clinical exploration. However, with regards 
to identifying lesions invisible to naked eye in the clinical 
examination, promising results have been shown using 
this method (4,9,17). 
Another author (18) reported that there was no evidence 
that the use of VELscope® in the routine clinical practice 
could be a measure to save lives by establishing an early 
diagnosis. Instead, he emphasizes that the adoption of 
this system for the diagnosis of cancer can be premature 
because it does not distinguish malignant from benign 
lesions, which may cause many false positives, causing 
insecurity and stress among patients. 
In a recent study, the results using Vizilite® and 

















VELscope® compared with histopathological analysis 
showed poor sensitivity and no significant predictive value 
in both systems. The false negative results were very high. 
Furthermore, researchers revealed that after the negative 
results provided by ViziLite® and VELscope®, which did not 
always coincided with the histopathological diagnosis, 
there was a feeling of insecurity for the clinician and the 
patient (11). Regarding the limitations of these studies, they 
diverge from the types of lesions included, since they were 
carried out among patients with the diagnosis of squamous 
cell carcinoma or severe dysplasia, confirmed by biopsy. In 
addition, the samples were small and were performed in 
the same center. 
In the present study, as the sample was composed of 
a small group, it does not fully represent a population 
and extrapolation of the data should be done carefully. 
Furthermore, our findings agree with other authors’ 
opinion regarding the need of previous training, which, 
combined with the difficulty of taking pictures with this 
system, makes it difficult to use on a daily basis in general 
practice (3,17,19-22). 
Farah (16) found adequate sensitivity and specificity, 
disagreeing with other  studies, ours included, that 
observed worse results for the autofluorescence system 
(11,18). We think that a well-trained human eye provides, 
as demonstrated in our comparative study, results that are 
difficult to improve by complementary optical methods, 
which are also very technique-sensitive. For these reasons 
we think that training the dentist in oral pathology is 
essential as a method of screening for premalignant lesions.
The World Health Organization (WHO) has clearly 
determined that early diagnosis is the best way to prevent 
and control oral cancer. Many authors agree that the 
use of devices that aid visualization can help identifying 
the margins of the lesion and its extension when an 
unmagnified view is not available. The findings of this study 
corroborate the discussions on the literature that previous 
training is necessary before operating autofluorescence 
devices, therefore it was difficult to obtain quality pictures 
for our records.
From the results of the present study, no clinical benefits 
were obtained from the use of VELscope® system.
Resumo 
O objetivo deste estudo foi determinar a precisão das técnicas de 
autofluorescência para o diagnóstico de lesões da mucosa oral, 
utilizando como padrão de referência para comparação o diagnóstico 
visual feito por um especialista clínico. Um estudo piloto foi realizado 
com 60 pacientes, divididos em um grupo controle sem patologia da 
mucosa oral e um grupo de estudo com história clínica conhecida de 
patologia da mucosa oral. Ambos os grupos foram examinados por um 
especialista em medicina oral e por um dentista clínico geral que usou 
o sistema VELscope®, que aplica a visualização por fluorescência para 
identificar anormalidades do tecido da mucosa oral. Usando o sistema 
VELscope®, o dentista geral realizou sobrediagnóstico em dois casos 
e subdiagnóstico em um caso. A sensibilidade e especificidade para o 
especialista em medicina oral foi 1 (IC 95%: 0,884 a 1). Para o dentista 
geral, a sensibilidade não melhorou significativamente com o uso do 
sistema de VELscope® [0,53 (95% CI: 0,343 to 0,717) versus 0,49 (95% 
CI: 0,406 to 0,773)], e a especificidade foi de 0,80 (IC de 95% : 0,614-
0,923). Uma limitação do estudo é o pequeno tamanho da amostra, 
que não representa totalmente a população e a extrapolação dos dados 
deve ser feita com cuidado. Com base nos resultados obtidos, não houve 
benefícios clínicos com o uso do sistema VELscope®.
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